ZYZhoujie Ye

Zhoujie Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhoujie Ye has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Liping Zhu

    Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University

    4 shared publications
  • Meijia Lin

    Department of Pathology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China

    2 shared publications
  • Xinrui Wang

    Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, 350013, China

    2 shared publications
  • Aizhu Lin

    1 shared publication
  • Dongliang Lin

    Department of Thoracic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University

    1 shared publication
  • Haile Yu

    1 shared publication

Latest Publications

  • Open Access

    NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma

    by Jinlong Huang, Liping Zhu, Weiqing Zhang, Dongliang Lin, Luoyu Lian, Wenshan Hong, Zhendong Xu, Zhoujie Ye

    Lung squamous cell carcinoma (LUSC) is associated with limited therapeutic options and poor clinical prognosis. The Octamer nucleotide--binding transcription factor (NONO), which lacks the POU domain, is implicated in nearly every aspect of gene regulation. It participates in various biological processes including cell proliferation, apoptosis, migration, and DNA damage repair. In this study, we report elevated expression of the NONO gene in LUSC as identified through tumor databases. Our biological function experiments confirmed that NONO promotes the proliferation of LUSC cells by inhibiting apoptosis and enhances the tumor cells’ capabilities for invasion and metastasis. Through the mediation of the PI3K/AKT signaling pathway, NONO regulates downstream molecules such as FOXO1 and GSK3β, which are related to cell proliferation and apoptosis. It participates in the regulation of LUSC cell proliferation, invasion and metastasis, and can serve as a potential clinical target for LUSC, providing ideas for exploring new treatment methods.

  • Open Access

    KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan‐Cancer Analysis

    by Liping Zhu, Xiaoyan Peng, Haile Yu, Xiaolu Fan, Zhoujie Ye

    Dysregulation of histone modifications contributes to the development of cancer. The loss of methylation on histone H3 and H4 and the loss of acetylation serve as indicators of tumors. Histone demethylase KDM3B, which contains a JmjC domain, plays an important role in tumorigenesis and development by removing H3K9me1/2 methylation. It also has a significant impact on regulating different types of cancer. KDM3B′s role in prognosis and tumor formation in cancer has not been thoroughly studied. In this study, we analyzed KDM3B expression data from the TCGA database in a pan‐cancer analysis. Our results show that KDM3B is highly expressed in many cancer types and is closely associated with poor prognosis. KDM3B expression is associated with immune checkpoint activities, lymphocyte infiltration, and immune landscape changes, suggesting that KDM3B could be a target for cancer therapy.

  • Open Access

    HER2 and Epigenetic Modifications in Tumorigenesis: Mechanisms and Therapeutic Implications

    by Zhoujie Ye, Haile Yu, Liping Zhu, Xiaolu Fan, Aizhu Lin, Xinrui Wang

    Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that plays a pivotal role in the development and progression of cancers, particularly in breast and gastric cancers. While HER2 overexpression is commonly attributed to gene amplification, recent studies indicate that epigenetic modifications, such as DNA methylation, histone modification, and non-coding RNA interference, are also critical in regulating HER2 expression and activity. This article will focus on the relationship between HER2 and epigenetic modification.


  • Deciphering the Epigenetic Landscape: Placental Development and Its Role in Pregnancy Outcomes

    by Yujia Chen, Zhoujie Ye, Meijia Lin, Liping Zhu, Liangpu Xu, Xinrui Wang

    The placenta stands out as a unique, transitory, and multifaceted organ, essential to the optimal growth and maturation of the fetus. Functioning as a vital nexus between the maternal and fetal circulatory systems, it oversees the critical exchange of nutrients and waste. This exchange is facilitated by placental cells, known as trophoblasts, which adeptly invade and remodel uterine blood vessels. Deviations in placental development underpin a slew of pregnancy complications, notably fetal growth restriction (FGR), preeclampsia (PE), recurrent spontaneous abortions (RSA), and preterm birth. Central to placental function and development is epigenetic regulation. Despite its importance, the intricate mechanisms by which epigenetics influence the placenta are not entirely elucidated. Recently, the scientific community has turned its focus to parsing out the epigenetic alterations during placental development, such as variations in promoter DNA methylation, genomic imprints, and shifts in non-coding RNA expression. By establishing correlations between epigenetic shifts in the placenta and pregnancy complications, researchers are unearthing invaluable insights into the biology and pathophysiology of these conditions. This review seeks to synthesize the latest findings on placental epigenetic regulation, spotlighting its crucial role in shaping fetal growth trajectories and development. Through this lens, we underscore the overarching significance of the placenta in the larger narrative of gestational health. Graphical Abstract


  • Open Access

    GAS-STING: a classical DNA recognition pathways to tumor therapy

    by Xinrui Wang, Meijia Lin, Liping Zhu, Zhoujie Ye

    Cyclic GMP-AMP synthetase (cGAS), recognized as the primary DNA sensor within cells, possesses the capability to identify foreign DNA molecules along with free DNA fragments. This identification process facilitates the production of type I IFNs through the activator of the interferon gene (STING) which induces the phosphorylation of downstream transcription factors. This action characterizes the most archetypal biological functionality of the cGAS-STING pathway. When treated with anti-tumor agents, cells experience DNA damage that triggers activation of the cGAS-STING pathway, culminating in the expression of type I IFNs and associated downstream interferon-stimulated genes. cGAS-STING is one of the important innate immune pathways,the role of type I IFNs in the articulation between innate immunity and T-cell antitumour immunity.type I IFNs promote the recruitment and activation of inflammatory cells (including NK cells) at the tumor site.Type I IFNs also can promote the activation and maturation of dendritic cel(DC), improve the antigen presentation of CD4+T lymphocytes, and enhance the cross-presentation of CD8+T lymphocytes to upregulating anti-tumor responses. This review discussed the cGAS-STING signaling and its mechanism and biological function in traditional tumor therapy and immunotherapy.


  • Open Access

    HCFC1R1 Deficiency Blocks Herpes Simplex Virus-1 Infection by Inhibiting Nuclear Translocation of HCFC1 and VP16

    by Yangkun Shen, Zhoujie Ye, Xiangqian Zhao, Zhihua Feng, Jinfeng Chen, Lei Yang, Qi Chen

    Upon HSV-1 infection, viral protein 16 (VP16), supported by Host Cell Factor C1 (HCFC1), is rapidly transported into the nucleus, and help to express a series of HSV-1 immediate-early proteins to begin its lytic replication. However, no direct evidence has shown if the HCFC1 deficiency can affect the proliferation of HSV-1 so far. Here, we showed that the HCFC1 deficiency led to a strong resistance to HSV-1 infection. Moreover, we identified Host Cell Factor C1 Regulator 1 (HCFC1R1) as a new host factor acting early in HSV infection for the transport of the HSV-1 capsid to the nucleus. The HCFC1R1 deficiency also led to a strong resistance to HSV-1 infection. The HCFC1R1 deficiency did not affect the attachment of HSV-1 to host cells but act early in HSV-1 infection by perturbing the formation of HCFC1/VP16 complex. Remarkably, in addition to wild-type HSV-1 infection, the host cells in the absence of either HCFC1 or HCFC1R1 showed strong resistant to the infection of TK-deficient HSV-1, which strain can course severe symptoms and tolerate to the current anti-HSV drug Acyclovir. Our data suggest that HCFC1 or HCFC1R1 may be used as the novel target for developing anti-HSV-1 therapies. IMPORTANCE: Herpes simplex virus-1 (HSV-1) is widely spread in the human population and can cause a variety of herpetic diseases. Acyclovir, a guanosine analogue that targets the TK protein of HSV-1, is the first specific and selective anti-HSV-1 drug. However, the rapid emergence of resistant HSV-1 strains is occurring worldwide, endangering the efficacy of Acyclovir. Alternatively, targeting host factors is another strategy to stop HSV-1 infection. Unfortunately, although the HSV-1’s receptor, Nectin-1, was discovered in 1998, no effective antiviral drug to date has been developed by targeting Nectin-1. Targeting multiple pathways is the ultimate choice to prevent HSV-1 infection. Here we demonstrated that the deletion of HCFC1 or HCFC1R1 exhibits a strong inhibitory effect on both wild-type and TK-deficient HSV-1. Overall, we present evidence that HCFC1 or HCFC1R1 may be used as the novel target for developing anti-HSV-1 therapies with a defined mechanism of action.